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ChemopreventionThe Human Papillomavirus type-16 (HPV-16) E6 and E7 oncogenes are selectively retained and expressed in
cervical carcinomas, and expression of E6 and E7 is sufﬁcient to immortalize human cervical epithelial cells.
Expression of the epidermal growth factor receptor (EGFR) is often increased in cervical dysplasia and carci-
noma, and HPV oncoproteins stimulate cell growth via the EGFR pathway. We found that erlotinib, a speciﬁc
inhibitor of EGFR tyrosine kinase activity, prevented immortalization of cultured human cervical epithelial
cells by the complete HPV-16 genome or the E6/E7 oncogenes. Erlotinib stimulated apoptosis in cells that
expressed HPV-16 E6/E7 proteins and induced senescence in a subpopulation of cells that did not undergo
apoptosis. Since immortalization by HPV E6/E7 is an important early event in cervical carcinogenesis, the
EGFR is a potential target for chemoprevention or therapy in women who have a high risk for cervical cancer.dworth).
rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Cervical cancer is a major cause of death in women worldwide.
The incidence is high in underdeveloped countries and in individuals
who have low socioeconomic status or are immune compromised
(Schiffman and Brinton, 1995). The major risk factor for cervical can-
cer is persistent infection with high-risk types of human papillomavi-
rus (HPV) (Schiffman and Brinton, 1995). The HPV E6 and E7 genes
from high-risk HPV types (HPV-16 and -18) are sufﬁcient to immor-
talize human epithelial cells (Hawley-Nelson et al., 1989; Munger et
al., 1989), and these genes are selectively retained and expressed in
most cervical cancers (von Knebel Doeberitz et al., 1992). The major-
ity of HPV infections are eliminated by the host's immune response,
but individuals who have compromised immunity (AIDS patients or
transplant recipients) develop persistent infections with multiple
HPV types (Palefsky, 2009). Persistent infection with high risk HPVs
and immortalization of infected cells are important early events in
the development of cervical cancer.
Therapy for cervical cancer involves surgery, chemotherapy or ra-
diation, and the 5-year survival for women with invasive cervicalcancer is poor. In contrast, if the disease is detected early by PAP
screening or HPV testing, the prognosis is good (Arbyn et al., 2009).
Chemoprevention of cervical cancer has been explored in several clin-
ical trials, but most agents have not been effective (Vlastos et al.,
2003). Recently, prophylactic vaccines have been shown to prevent
HPV infection (Campo and Roden, 2010). These vaccines induce
type-speciﬁc immunity to the two most common high risk HPVs
(HPV-16 and HPV-18) which account for approximately 70% of cervi-
cal cancers. However, they are not effective in women who have
existing HPV infections. Due to the long latency of cervical carcino-
genesis, the prophylactic vaccine is unlikely to have a major impact
on the incidence of cervical cancer for many years. In addition, the
vaccine may be less effective in women who are immune deﬁcient
and infected with multiple high-risk types (AIDS patients and trans-
plant recipients) (McKenzie et al., 2010). Thus, women who have a
high risk for cervical cancer would beneﬁt from improved methods
for therapy or chemoprevention that target signal pathways critical
for cervical cancer development.
The epidermal growth factor receptor (EGFR) is a membrane tyro-
sine kinase expressed by most epithelial cells. Cervical epithelial cells
secrete several EGF-like growth factors that activate the EGFR by au-
tocrine and paracrine pathways (Woodworth et al., 1995). Ligand
binding leads to receptor dimerization, tyrosine kinase activation
and stimulation of intracellular signal pathways that regulate growth,
20 C.D. Woodworth et al. / Virology 421 (2011) 19–27survival, motility, and angiogenesis. EGFR signaling is important for
normal cell function, but inappropriate activation or over expression
can contribute to malignant development (Normanno et al., 2005).
Over expression of the EGFR or mutations in the EGFR gene have
been implicated in the pathogenesis of multiple types of human can-
cer. The EGFR is frequently over expressed in cervical dysplasia and
cervical cancer, and patients who have high levels of EGFR in their tu-
mors have a poor prognosis (Kersemaekers et al., 1999). The HPV-16
E6 and E7 proteins stimulate EGFR expression on epithelial cells
(Akerman et al., 2001; Sizemore et al., 1998) and the HPV E5 protein
increases recycling of the EGFR to the cell surface (Straight et al.,
1995) and alters EGF endocytic trafﬁcking (Suprynowicz et al.,
2010). Targeted disruption of the EGFR gene inhibits development
of papillomas and carcinomas from HPV-immortalized epithelial
cells in mice (Woodworth et al., 2000). Together, these observations
suggest that activation of the EGFR is important for the HPV life
cycle and progression to cervical cancer.
Inhibitors of the EGFR have been used for therapy of several types
of human cancer (Chen et al., 2009). The two major classes of inhibi-
tors are monoclonal antibodies that interfere with ligand binding and
small molecule kinase inhibitors that selectively block receptor acti-
vation. Erlotinib is a small molecule inhibitor that competes revers-
ibly with ATP for binding to the tyrosine kinase domain of the EGFR.
Erlotinib is administered to patients orally and the side effects are
usually well tolerated (Li and Perez-Soler, 2009). Erlotinib has been
approved by the FDA for treatment of recurrent non-small cell lung
cancer and for ﬁrst-line treatment of advanced pancreatic cancer
with gemcitabine (Iyer and Bharthuar, 2010). Given the importance
of EGFR signaling to the HPV life cycle, we investigated whether erlo-
tinib had activity against HPV-infected cervical cells. We observed
that erlotinib prevented immortalization of cultured human cervical
epithelial cells by the complete HPV-16 genome or the E6/E7 genes.
This response was associated with induction of apoptosis in cells
that express E6/E7 and stimulation of senescence in surviving cells.
These results suggest that the EGFR might be an effective target for
chemoprevention in women who have a high risk of cervical cancer.
Results
Erlotinib prevents immortalization by the complete HPV-16 genome
Primary cultures of human cervical epithelial cells were trans-
fected with a plasmid containing the complete HPV-16 genome plus
the neomycin resistance gene. After selection in medium with G418,
stably transfected cells were maintained in keratinocyte serum-free
medium (KSFM) until they became senescent or grew continuously.
As a negative control for immortalization, cultures were transfected
with the plasmid containing only the neomycin resistance gene (no
HPV). Cells transfected with HPV-16 grew continuously and became
immortalized (Table 1, untreated), although there was evidence of
crisis (slow growth and cell lysis) in some dishes. Cells transfected
with only the neo gene became senescent after 2 to 3 passagesTable 1
Frequency of immortalization of human cervical cells by the complete HPV-16 genome
after treatment with erlotinib.
Erlotinib KSFMa W/o EGF
HCX-1 HCX-2 HCX-3 HCX-1 HCX-2 HCX-3
Untreated 6/6b 6/6 5/5 6/6 6/6 6/6
0.1 μM 5/6 3/6 5/6 0/5 0/6 0/6
0.3 μM 2/5 0/5 0/6 0/5 0/6 0/6
1.0 μM 0/6 0/6 0/6 0/6 0/5 0/6
a Immortalization assays were performed in KSFMwith 5 ng/ml EGF (3 left columns)
or KSFM without EGF (3 right columns). Each column represents an independent ex-
periment using cells from a different sample of cervix.
b Number of wells with immortal cells/the total number of wells examined.(data not shown). Senescence occurred after a total of 40–60 popula-
tion doublings and 20–40 population doublings were required to es-
tablish and transfect cell cultures. Treatment with erlotinib
signiﬁcantly (p≤0.05) decreased the percentage of cultures that con-
tained immortal cells in 3 independent experiments using cells from
different individuals (Table 1). Erlotinib inhibited immortalization in
a dose-dependent manner over a range of drug concentrations be-
tween 0.1 and 1.0 μM, and 0.2 μM of the drug inhibited immortaliza-
tion by 50% (ID50).
The serum-free medium used to culture primary cervical cells con-
tains relatively high levels of recombinant EGF (5 ng/ml) which
raised the possibility that cells maintained in this medium might be-
come dependent on exogenous EGF for growth. Cultured cervical cells
produce multiple growth factors (including the EGF-family members
amphiregulin and TGF-α) that stimulate cells by autocrine and para-
crine methods (Woodworth et al., 1995). Therefore, we investigated
whether erlotinib prevented immortalization when cells were main-
tained in medium without exogenous EGF. Immortalization assays
were repeated in KSFM lacking EGF and bovine pituitary extract
(which contains EGF). Under these conditions, HPV-16 transfected
cells grew more slowly but continued to form immortal colonies
(Table 1). In 3 independent experiments, erlotinib completely pre-
vented immortalization by HPV-16. Immortalization was prevented
by low concentrations of erlotinib (0.1 μM) that were not effective
when assays were performed in complete KSFM with exogenous
EGF (Table 1). Because erlotinib inhibits the EGFR in a reversible man-
ner, high concentrations of EGF might compete more effectively with
the drug for receptor activation. These results suggest that paracrine
or autocrine growth stimulation by endogenously produced EGF-
family growth factors is important for immortalization of cervical
epithelial cells, and that erlotinib prevented immortalization more
effectively in the absence of high levels of recombinant EGF.
Erlotinib prevents immortalization by HPV-16 E6 and E7 genes
The complete HPV-16 genome encodes 3 oncoproteins including
E5, E6, and E7. The E6 and E7 proteins are sufﬁcient for immortaliza-
tion (Munger et al., 1989), but E5 increases signaling through the
EGFR (Straight et al., 1995) and alters epithelial growth via an EGFR
dependent pathway (Genther Williams et al., 2005). Therefore, we
examined whether erlotinib could prevent immortalization in the ab-
sence of E5. Cervical cells were infected with retroviruses encoding
the HPV-16 E6 and E7 genes but lacking the E5 gene. All viruses con-
tained the neomycin resistance gene (Halbert et al., 1991). As a neg-
ative control for immortalization, cultures were infected with
retroviruses containing only the neo gene. Infected cultures were se-
lected in KSFM containing G418 and stably infected cells were plated
at clonal density (500 cells/60 mm dish). Cultures were fed every
2 days with KSFM or KSFM containing various concentrations of erlo-
tinib. We found that cultures infected with HPV-16 E6/E7 retrovirus
grew rapidly and became immortalized (Table 2, untreated). In con-
trast, cultures infected with only the neo gene became senescent
after 2 to 3 passages (data not shown). In 3 independent experimentsTable 2
Frequency of immortalization of human cervical cells by HPV-16 E6/E7 genes or by
SV40 after treatment with erlotinib.
Erlotinib HCX4–E6/E7 HCX5–E6/E7 HCX6–E6/E7 HCX7–SV40
untreated 5/5a 6/6 6/6 6/6
0.1 μM 4/6 4/6 5/6 5/6
0.3 μM 3/6 2/6 2/6 4/6
1.0 μM 0/6 0/6 0/5 0/5
3.0 μM 0/4 0/6 0/6 0/6
a Number of wells with immortal cells/ total number of wells examined. Each col-
umn represents an independent experiment using cells from a different sample of cer-
vix. All experiments were performed in KSFM plus 5 ng/ml EGF.
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21C.D. Woodworth et al. / Virology 421 (2011) 19–27using cells from different individuals, erlotinib signiﬁcantly (p≤0.05)
reduced the percentage of cultures that contained immortal cells
(Table 2). The ID50 for inhibition of immortalization by E6/E7 was
0.2 μM (the same as required for the complete HPV-16 genome).
These results indicate that expression of the E5 protein was not re-
quired for erlotinib-induced prevention of immortalization. Expres-
sion of E6 and E7 is regulated by the long terminal repeat in
retroviruses, whereas it is controlled by the natural HPV promoter
in the long control region (LCR) in the complete genome. Thus, erlo-
tinib blocks immortalization when E6/E7 expression is driven by ei-
ther promoter.
Interestingly, the effect of erlotinib on immortalization was not
speciﬁc for HPV-16. Erlotinib also blocked immortalization by Simian
Virus 40 (SV40) (Table 2), a DNA tumor virus that inactivates the p53
and retinoblastoma pathways similar to HPV. To conﬁrm that erloti-
nib prevented immortalization by speciﬁcally targeting the EGFR,
we tested a monoclonal antibody that blocks ligand binding to the
EGFR (Woodworth et al., 1995). In 2 independent experiments, this
antibody inhibited immortalization by the complete HPV-16 genome
or by E6/E7 retroviruses (Table 3). Similar results were obtained
using various concentrations of PD153035, another small molecule
kinase inhibitor that is speciﬁc for the EGFR (Table 3). In contrast,
an inhibitor of platelet derived growth factor receptor, AG1295, did
not prevent immortalization of cervical cells. Overall, these results in-
dicate that erlotinib prevents immortalization of cervical epithelial
cells that express HPV-16 E6/E7 genes by blocking signaling through
the EGFR.
Erlotinib inhibits clonal growth of cervical cells
A potential mechanism for prevention of immortalization is the
ability of erlotinib to block cell proliferation. We performed clonal
growth assays to measure growth inhibition. Cervical cells (either
E6/E7-infected, transfected with the HPV-16 genome, or transfected
with SV40 DNA) were plated at clonal density and fed KSFM±various
concentrations of erlotinib for 14–21 days. Untreated cultures grew
rapidly and formed colonies composed of loosely associated cells. In
contrast, cultures treated with erlotinib grew slowly and contained
small colonies of ﬂat, tightly associated cells (Fig. 1A). Erlotinib inhib-
ited colony formation in a dose-dependent manner (Fig. 1B) with an
ID50 of 0.7 μM. Thus, the ID50 for prevention of immortalization
(0.2 μM) was 3-fold lower that the ID50 for inhibition of colonyTable 3
Frequency of immortalization after treatment with a neutralizing antibody to the EGFR,
an alternate drug that speciﬁcally inhibits EGF-R kinase activation (PD153035), or an
inhibitor of the platelet derived growth factor receptor (AG1295).
Anti-EGF-R HPV16 E6/E7-1
Untreated 6/6a 6/6 ND
5 μg/ml 0/3 0/6 ND
10 μg/ml 0/3 0/6 ND
PD153035 HPV16 E6/E7-1 E6/E7-2
Untreated 6/6 5/5 5/6
0.1 μM 3/6 2/6 4/6
0.3 μM 1/6 2/5 0/5
1.0 μM 0/6 0/5 0/6
AG1295 HPV16 E6/E7-1
Untreated 6/6 5/5 ND
1.0 μM 5/5 6/6 ND
a Number of wells with immortal cells/ total number of wells examined. Each col-
umn represents an independent experiment using cells from a different sample of cer-
vix. Cultures were transfected with the complete HPV-16 genome or infected with
retroviruses encoding E6/E7. Experiments using anti-EGF-R antibody were performed
in KSFM without EGF, and those using AG1295 or PD153035 used KSFM with 5 ng/ml
EGF. ND=not done.
normal HCX
HPV-16 E6/E7
immortal cell lines
cancer cell lines
Fig. 1. Erlotinib inhibits clonal growth. A. Phase contrast micrographs showing cell
growth in KSFM without (left) or with erlotinib (right). B. Erlotinib inhibits colony for-
mation in a dose-dependent manner. Cervical epithelial cells were transfected with the
complete HPV-16 genome, SV40 DNA, or infected with retroviruses encoding HPV-16
E6/E7 and then treated with various doses of erlotinib for 10 days in KSFM or KSFM
without added EGF and BPE. For each experiment colony number was determined by
counting cells in 3 replicate dishes from 3 different donors. C. Erlotinib inhibits colony
formation by cells at progressive stages leading to cancer. Three normal cervical cell
strains (normal HCX), 3 strains infected with HPV-16 E6/E7 retroviruses, 3 HPV-16-
immortal cell lines, and 3 cervical carcinoma cell lines were treated with erlotinib
and the mean cloning efﬁciency was measured. Points represent percent colony forma-
tion±standard deviation in 3 independent experiments.formation. Erlotinib also blocked colony formation by SV40-
expressing cells. Interestingly, the lowest dose of erlotinib
(0.03 μM) stimulated a small but reproducible increase in colony
formation. When clonal growth assays were performed without ex-
ogenous EGF in the culture medium, cells continued to grow slowly
and form colonies. Erlotinib inhibited clonal growth of cells trans-
fected with HPV-16 or E6/E7 signiﬁcantly more strongly (p≤0.05)
in the absence of EGF (Fig. 1B).
22 C.D. Woodworth et al. / Virology 421 (2011) 19–27We examined whether cells at progressive stages leading to cervi-
cal cancer differed in susceptibility to growth inhibition by erlotinib.
We used clonal growth assays to compare cervical cells from 3 differ-
ent normal individuals, 3 cell cultures infected with HPV-16 E6/E7
retroviruses, 3 different HPV-16 immortalized cell lines, and 3 differ-
ent cervical carcinoma cell lines (Woodworth et al., 1995). Erlotinib
inhibited colony formation by normal cervical cells as effectively as
cells that expressed HPV (Fig. 1C). Thus, growth inhibition by erloti-
nib was not speciﬁc for HPV-expressing cells. The dose of erlotinib
that inhibited clonal growth by 50% (ID50) was similar for normal
cells, E6/E7-infected cells and HPV-16-immortalized cell lines, but
the ID50 was variable in cervical carcinoma cell lines (data not
shown).
Erlotinib stimulates apoptosis in cervical cells that express HPV-16
Phase contrast microscopy showed that erlotinib induced lysis of
cells and nuclear fragmentation that resembled apoptosis (Fig. 2A,
left). To measure the extent of cell lysis, cultures were stained with
DAPI, a DNA binding dye that penetrates cells that have membrane
damage. Cells expressing HPV-16 E6/E7 genes were stained brightly
by DAPI when treated with erlotinib (Fig. 2A, right) andphase contrast
untreated
erlotinib
A
B
Fig. 2. HPV-16 E6/E7 expression sensitizes cervical cells to erlotinib-mediated apoptosis. A. P
cells that were untreated (top) or treated with 1.0 μM erlotinib for 48 hours (bottom) and t
with erlotinib. Cells infected with HPV-16 E6/E7 were treated with EGFR inhibitor for 24 ho
somal DNA fragmentation. H2O2 served as a positive control for apoptosis.demonstrated nuclear condensation and fragmentation. One charac-
teristic feature of cells undergoing apoptosis is internucleosomal
DNA fragmentation. We validated our results using DAPI-staining
with a PCR based TUNEL assay to show that inhibition of the EGF-R
stimulated DNA fragmentation in a ladder-like pattern consistent
with apoptosis (Fig. 2B).
The extent of erlotinib-induced apoptosis was measured by count-
ing the percentage of DAPI-positive cells after 48 hours (Fig. 3A). Erlo-
tinib stimulated more apoptosis (p≤0.05) in 3 primary cultures of
cervical cells that were infected with HPV-16 E6/E7 than in 3 cultures
of cells that did not express HPV genes (Fig. 3A). The percentage of
dying cells continued to increase when treatment time was extended
to 72 hours (data not shown). To determine which HPV-16 gene was
important for sensitizing cells to apoptosis, 3 normal cervical cell cul-
tures were infected with retroviruses encoding HPV-16 E6, E7, E6/E7
or the empty vector. In 3 independent experiments, the E7 protein
sensitized cells to erlotinib-induced apoptosis most strongly whereas
E6/E7 or E6 alone were less effective but statistically different
(p≤0.05) than the empty vector (Fig. 3B). To determine whether
cells at progressive stages leading to cervical cancer were sensitive
to erlotinib-induced apoptosis, we compared 3 normal cervical cell
cultures, 3 cultures infected with HPV-16 E6/E7 retroviruses, 3 HPV-DAPI
hase contrast micrographs (left) and ﬂuorescent micrographs (right) of E6/E7-infected
hen stained by DAPI to label cells undergoing apoptosis. B. TUNEL assay of cells treated
urs and analyzed for apoptosis using a DNA Ladder Assay PCR kit to detect internucleo-
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Fig. 3. Erlotinib stimulates apoptosis in cells that contain HPV-16 DNA. A. Three primary cultures of normal cervical cells were infected with retroviruses encoding HPV-16 E6/E7 or
vector only (control) and apoptosis induced by erlotinib (1.0 μM for 48 hours) was measured. B. HPV-16 E7 is most effective in sensitizing cells to apoptosis. Three cultures from
different individuals were infected with retroviruses encoding HPV-16 E6, E7, E6/E7 or the empty vector (control), and treated with erlotinib. C. Erlotinib stimulates apoptosis in
HPV-containing cells at progressive stages leading to cancer. Three normal cervical cultures, 3 cultures infected with HPV-16 E6/E7 retroviruses, 3 HPV-immortal cell lines and 3
cervical carcinoma cell lines) were examined for susceptibility to erlotinib-induced apoptosis. Percent apoptosis (600 cells counted)=# DAPI-stained cells/600×100. The percent-
age of apoptotic cells was determined in triplicate dishes. Points represent the mean±standard deviation of the 3 experiments.
23C.D. Woodworth et al. / Virology 421 (2011) 19–27immortal cell lines and 3 cervical carcinoma cell lines. Erlotinib stim-
ulated apoptosis only in the cells that contained HPV-16 genes
(Fig. 3C, cancer, immortal and E6/E7-infected). Normal cultures
were signiﬁcantly less sensitive (p≤0.05). Erlotinib also stimulated
apoptosis in SV40-immortalized cervical cell lines by 10–15%. Overall,
these results indicate that erlotinib selectively kills cervical cells that
express HPV-16 or SV40 DNA. Thus, erlotinib-induced apoptosis may
eliminate HPV-expressing cells before they undergo immortalization.
Erlotinib induces premature senescence in a subpopulation of cells
Normal cervical epithelial cells grow for 2 to 3 passages before
they undergo replicative senescence. Erlotinib competes with ATP
for binding to the tyrosine kinase domain of the EGFR, and it blocks
EGFR activation in a competitive and potentially reversible manner.
We performed clonal growth assays to test whether erlotinib inhib-
ited growth reversibly or irreversibly. Cervical cells were infected
with HPV-16 E6/E7 retroviruses and plated at clonal density. Cultures
were treated continuously with erlotinib for speciﬁc intervals (0, 2, 4,
6, 8, 10, 12 or 14 days). Subsequently, cells from each treatment inter-
val were rinsed with fresh medium and allowed to form colonies in
KSFM without erlotinib for an additional 10 days. The ability to form
colonies decreased strongly after cells were treated with erlotinib
for 6–8 days (Fig. 4). During this time, a large percentage of surviving
cells became positive for β-galactosidase (Fig. 4), a marker for cell0
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Fig. 4. Erlotinib stimulates premature senescence in cells that fail to undergo apoptosis.
Cells were infected with retroviruses encoding HPV-16 E6 and E7 and cultured in KSFM
with 1.0 μM erlotinib for up to 14 days. At intervals of 2 days, triplicate cultures were
removed from the drug and fed with KSFM for an additional 10 days to allow colony
formation. Triplicate cultures were stained for β-galactosidase. Symbols represent the
mean and bars indicate±standard deviation.senescence. These results indicate that (1) erlotinib induced irrevers-
ible growth inhibition after 6–8 days, and (2) a subpopulation of E6/E7-
infected cells underwent senescence rather than apoptosis.
Erlotinib does not inhibit expression of HPV-16 E6 and E7 RNAs
Continued expression of the HPV-16 E6 and E7 genes is required
to maintain cell growth and the transformed phenotype of cervical
carcinoma cells (von Knebel Doeberitz et al., 1992). We examined
whether erlotinib might block growth and immortalization by inhi-
biting expression of E6 or E7 RNAs. Cervical cells were transfected
with the complete HPV-16 genome and then treated with either 0.1
or 1.0 μM erlotinib for 24 or 72 hours. RNA was extracted and ana-
lyzed for expression of E6 and E7 using real time PCR. As a negative
control, cells were treated with 3 ng/ml TGF-β1 which is known to in-
hibit E6 and E7 expression (Woodworth et al., 1990a). In two inde-
pendent experiments, erlotinib signiﬁcantly stimulated levels of E6
and E7 RNAs (Fig. 5A). In contrast, TGF-β1 signiﬁcantly inhibited
(p≤0.05) E6 and E7 RNAs. We used a reporter gene assay to check
our results. Normal cervical cells were transiently transfected with a
plasmid containing the HPV-16 long control region (LCR), the natural
HPV promoter, linked to the ﬁreﬂy luciferase gene (Khan et al., 1997).
Erlotinib did not signiﬁcantly alter HPV promoter activity in two inde-
pendent experiments (Fig. 5B).
We also examined whether erlotinib altered splicing of the E6/E7
transcript to yield more E6*/E7 RNA, which is known to inﬂuence rel-
ative expression of E6 and E7 proteins (Rosenberger et al., 2010).
HPV-16 transfected cervical cells expressed mainly the E6/E7 tran-
script and treatment with 1.0 μM erlotinib did not increase the ex-
pression of E6*/E7 RNA (data not shown). Overall, these results
suggest that erlotinib does not inhibit immortalization by decreasing
HPV-16 E6 and E7 RNA expression or splicing.
Discussion
The EGFR is frequently over expressed in cervical dysplasias
and cancers, and high level expression is associated with a poor
prognosis (Kersemaekers et al., 1999). The HPV-16 oncoproteins
E5, E6 and E7 directly stimulate signaling via the EGFR (Akerman
et al., 2001; Sizemore et al., 1998; Straight et al., 1995) suggesting
that this pathway is important for the HPV life cycle. We found
that erlotinib, a kinase inhibitor speciﬁc for the EGFR, prevented
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Fig. 5. Erlotinib increases expression of HPV-16 E6/E7 RNAs in cervical cells. A. Real
time PCR analysis of HPV-16 E6 and E7 RNAs in cells that were transfected with
HPV-16 and then treated with erlotinib at 0.1 or 1.0 μM for 24 or 72 hours. Cells
were treated with 3 ng/ml TGF-β1 as a positive control. Bars represent the mean of
two independent experiments±standard error, and asterisks are values that differ sta-
tistically (p≤0.05) from controls. B. Reporter gene assay to measure activity of HPV-16
LCR in cervical cells after treatment with various concentrations of erlotinib for 6, 24 or
48 hours. Points represent the mean of 3 wells±standard error.
24 C.D. Woodworth et al. / Virology 421 (2011) 19–27immortalization of cultured human cervical epithelial cells by the
complete HPV-16 genome. Inhibition of immortalization did not
depend on the presence of the E5 oncoprotein because erlotinib
also prevented immortalization by E6/E7 genes alone. We found
that erlotinib inhibited clonal growth, stimulated apoptosis, and
induced premature senescence in E6/E7-expressing cervical cells.
The concentrations of erlotinib that inhibited immortalization
and stimulated apoptosis in vitro were comparable to the steady
state plasma concentrations of erlotinib in treated patients
(Smith, 2005). Persistent infection with high risk HPVs and subse-
quent immortalization of cervical cells are important early events
in cervical carcinogenesis. Our results indicate that blocking EGFR
function prevents immortalization by HPV-16 E6 and E7 genes in
vitro. Thus, erlotinib or other EGFR inhibitors may represent a
novel and noninvasive method for chemoprevention or therapy
of premalignant cervical disease.
Our results suggest that erlotinib stimulates apoptosis in cells that
express HPV-16. The drug induced apoptosis in cervical carcinoma
cell lines, HPV-16-immortalized cervical cell lines, and HPV-16- or
SV-40-transfected normal cell cultures. In contrast, erlotinib did not
stimulate apoptosis in normal cervical epithelial cells. These results
are consistent with work showing that inhibition of the EGFR by tyr-
phostin AG1478 stimulated apoptosis of HPV-16 immortalized fore-
skin keratinocytes (Ben-Bassat et al., 1999). Our results extend thisﬁnding to cervical cells and demonstrate that the E7 protein is pri-
marily responsible for sensitizing cells to apoptosis in response to
EGFR inhibition. Erlotinib-induced apoptosis may be important for
preventing cell immortalization. Prior to immortalization by HPV-
16, cells enter a stage of crisis where they develop genetic instability
and may undergo death. Our results indicate that erlotinib sensitizes
HPV-16 expressing cells to apoptosis which might prevent progres-
sion through crisis and immortalization.
Erlotinib is a reversible inhibitor of the EGFR that competes with
ATP for binding to the tyrosine kinase domain of the receptor. Erloti-
nib is known to induce p27KIP1 up-regulation and growth arrest in
the G1 phase of the cell cycle (Ling et al., 2007). We found that
short term treatment with erlotinib inhibited growth of HPV-16
expressing cells in a reversible manner. Cells resumed colony forma-
tion after removal of the drug. However, chronic exposure to erlotinib
induced irreversible growth arrest and premature senescence in a
proportion of cells that did not undergo apoptosis. Erlotinib-treated
cells lost the ability to form colonies and expressed the senescence
marker β-galactosidase after 6 days of continuous treatment. Previ-
ous studies have shown that EGFR inhibitors stimulate premature se-
nescence in vivo and in vitro, and it has been hypothesized that
senescence is an important anti-tumor mechanism (Hotta et al.,
2007). In this regard, inhibition of the EGFR is known to suppress
the activity of telomerase in cancer cells (Budiyanto et al., 2003).
We observed that a few cells escaped senescence and became immor-
talized in the presence of erlotinib. These immortal cell lines had in-
creased resistance to the drug (data not shown).
Continued expression of the HPV-16 E6 and E7 proteins is re-
quired to maintain growth of HPV-immortalized cells and cervical
carcinoma cell lines (von Knebel Doeberitz et al., 1992). We found
that erlotinib did not decrease expression of E6 and E7 RNAs in trans-
fected cervical epithelial cells. In fact, erlotinib signiﬁcantly stimulat-
ed expression of E6 and E7 RNAs. The biological signiﬁcance of this
ﬁnding is unclear. Erlotinib did not alter expression from the HPV-
16 LCR in reporter gene assays. We also found that erlotinib inhibited
immortalization by SV40, suggesting that the drug did not prevent
immortalization by speciﬁcally targeting HPV gene expression. Re-
cently, others have reported that inhibition of the EGFR by 30.0 μM
AG1478 altered splicing of E6/E7 RNAs to favor production of the
E6*/E7 transcript, which decreased levels of E6 RNA and increased
levels of p53 in keratinocytes (Rosenberger et al., 2010). We did not
see differences in splicing in our experiments. Thus, inhibition of
the EGFR may interfere with HPV-16 E6/E7 expression in some cell
systems, but this effect was not critical for prevention of immortaliza-
tion by HPV-16 in cultured cervical cells.
Clinical trials for chemoprevention of cervical cancer by several
natural products have not yielded promising results (Sasieni, 2006).
In contrast, the HPV prophylactic vaccine prevents infection by
HPV-16 and -18 (Campo and Roden, 2010), and presumably will re-
duce cancer caused by these two high risk types (approximately
70% of cervical cancers). Due to the long latency of cervical carcino-
genesis, the prophylactic vaccine is not likely to have a major impact
on the overall incidence of cervical cancer for many years. In addition,
the vaccine may be less effective in high risk populations that are im-
mune compromised, such as AIDs patients or transplant recipients
(Palefsky, 2009). Most importantly, the vaccine does not help
women who already have HPV infections. Thus, HPV-infected
women who have a high risk for cervical cancer would beneﬁt from
improved methods of chemoprevention or therapy that target signal
pathways critical for cervical cancer development. Immortalization
by HPV is a relevant target, and our results suggest that erlotinib
might have a role in individuals with high risk for cervical cancer or
other HPV-associated malignancies. Treatment with erlotinib causes
side effects that are manageable, including skin rash and diarrhea
(Iyer and Bharthuar, 2010; Li and Perez-Soler, 2009), and serious ef-
fects occur rarely. Currently, erlotinib is under evaluation in a
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and neck cancer (William et al., 2009).
Erlotinib stimulated apoptosis and inhibited clonal growth of cul-
tured cervical carcinoma cells, although the effectiveness of inhibition
(ID50) varied in different lines. Erlotinib has been approved by the
FDA for treatment of recurrent non-small cell lung cancer and for
ﬁrst-line treatment of advanced pancreatic cancer with gemcitabine
(Iyer and Bharthuar, 2010). Therefore, it is reasonable to test its tox-
icity (Nogueira-Rodrigues et al., 2008; Perez Rodrigo et al., 2009)
and therapeutic activity for cervical cancer. Recently, erlotinib was
shown to be ineffective as monotherapy for patients with recurrent
cervical cancer in a phase II trial (Schilder et al., 2009). Similar results
were reported for geﬁtinib (Goncalves et al., 2008), another EGFR ki-
nase inhibitor. Several studies have shown that patients who harbor
mutations in the EGFR gene have a high rate of response to erlotinib
(Lynch et al., 2004), but these mutations appear to be rare in cervical
cancers and dysplasias (Arias-Pulido et al., 2008). In the future, EGFR
inhibitors may be most effective therapeutically in patients who are
preselected for genetic susceptibility (Carter et al., 2009; Vaidya et
al., 2005), or when they are used in combination with other targeted
therapies (Gossage and Eisen, 2010; Johnson and Brown, 2010).
Conclusions
We show that erlotinib, a speciﬁc inhibitor of EGFR tyrosine kinase
activity, prevented immortalization of human cervical epithelial cells
by HPV-16. Erlotinib sensitized HPV-16-expressing cells to apoptosis
and induced senescence in a subpopulation of surviving cells. These
results indicate that EGFR inhibitors may be useful for chemopreven-
tion in women who have a high risk for developing cervical cancer.
Materials and methods
Cervical cell culture
Cervical tissue was purchased from the Cooperative Human Tissue
Network. Specimens were removed after hysterectomy for nonmalig-
nant disease. Tissues were collected in RPMI medium with 10% fetal
bovine serum plus antibiotics and used within 24 hours. Cervical ep-
ithelial cells were isolated using a two step enzymatic digestion
(Woodworth and Simpson, 1993). Brieﬂy, each tissue was digested
for 16 hours at 4°C in dispase (BD Biosciences) and the epithelium
was removed by scraping. The epithelial sheet was cut into 1 mm2
pieces and digested in 0.25% trypsin at 37°C for 10 minutes. Trypsin
was neutralized by addition of fetal bovine serum and cells were col-
lected by centrifugation at 2000 ×g. Normal epithelial cells, HPV-16
immortalized cells (Woodworth et al., 1990a, 1990b) and cervical
carcinoma cell lines (Woodworth et al., 1995) were cultured in Kera-
tinocyte Serum-Free Medium (KSFM, Invitrogen) or KSFM lacking
EGF and bovine pituitary extract.
Transfection or retrovirus infection with HPV-16 genes
HPV does not undergo efﬁcient productive infection in vitro, there-
fore, we introduced HPV genes into cultured cervical cells by transfec-
tion of the HPV-16 genome or infection with recombinant HPV-16
retroviruses (Halbert et al., 1991). Secondary cultures were trans-
fected with a plasmid containing the complete HPV-16 genome plus
the neomycin resistance gene (Woodworth et al., 1988) using lipofec-
tamine (Invitrogen). Transfected cultures were split into 6×60 mm
dishes and selected for 48 hours in KSFM containing 100 μg/ml G418.
These cultures were used directly for immortalization and clonal
growth assays. For retrovirus infection, secondary cultures were
infected with high-titer retroviruses (Woodworth et al., 1992)
encoding HPV-16 E6, E7, or E6/E7 genes inserted into the vector
pLXSN, which contains the neomycin resistance gene (Halbert etal., 1991). Infection was performed for 3 hours in medium with
10 ng/ml polybrene with rocking every 15 minutes. Subsequently, me-
dium was changed and cells grew for 24 hours before cultures were
split 1:3. After 24 hours, infected cells were selected by growth for
2 days in KSFM containing 200 μg/ml G418 and used immediately for
experiments.Immortalization assay
Immortalization assays were performed after transfection with
the complete HPV-16 genome or infection with HPV-16 E6/E7-
containing retroviruses. For retrovirus-based assays, cells were plated
at clonal density (500 cells/60 mm dish) in 6×60 mm dishes for each
experimental group. After 24 hours, cultures were treated with KSFM
containing erlotinib (OSI Pharmaceuticals) at doses of 0.03, 0.1, 0.3,
1.0 or 3.0 μM. As controls, cultures were treated with 0.1% DMSO
(used to dissolve erlotinib), AG1295 (BD Biosciences) a speciﬁc inhib-
itor of platelet derived growth factor receptor that does not inhibit
EGFR tyrosine kinase activity, PD153035 (EMD4 Biosciences) a specif-
ic inhibitor of the EGFR, or with a monoclonal antibody that blocks
binding to the EGFR (LA1, Millipore). Experiments to verify inhibition
of the EGFR using an anti phospho EGFR antibody in Western blots
were performed previously (Woodworth et al., 2005). Cells infected
with retroviruses containing only the pLXSN vector (lacking HPV-16
genes) served as the negative control for immortalization. Transfection-
based assays were performed on cultures after transfection with a plas-
mid containing the complete HPV-16 genome plus the neomycin resis-
tance gene (Woodworth et al., 1988). After selection for stably
transfected cells using G418, cultures were fed with fresh KSFM contain-
ing erlotinib every 2 days. Immortalization was measured by pooling the
colonies in each dish and subculturing cells continually in the presence or
absence of erlotinib. Cervical cells became senescent 2 or 3 passages after
introduction of HPV-16 genes (approximately 40–60 population dou-
blings). About 30–40 population doublings were required to isolate pri-
mary cultures and transfect/infect with HPV-16 genes. Cells transfected
with the neomycin resistance gene alone served as a negative control
for immortalization. Cells transfected with a plasmid encoding the Sim-
ian Virus-40 (SV40) genome (Woodworth et al., 1986) served as a con-
trol for determining speciﬁcity of drug effects for HPV-16.Clonal growth assay
Cells were plated as described in immortalization assays. Cultures
were treated with erlotinib continuously for 14 (retrovirus-infected)
or 21 days (transfected). After colonies became visible, dishes were
ﬁxed and stained with Giemsa to identify colonies. A colony was de-
ﬁned as 50 or more cells.Apoptosis assay
Cells were plated at a density of 5×105 cells/60 mm dish and then
treated with erlotinib for 24 or 48 hours at concentrations ranging
from 0.03 to 1.0 μM. A DNA Ladder Assay PCR kit (Maxim Biotech,
Inc) was used to detect fragmentation between nucleosomes as de-
scribed (Iglesias et al., 1998). To determine the percentage of apopto-
tic cells, cultures were stained with DAPI (1 μg/ml) and examined
under UV light. Apoptotic cells were identiﬁed by condensed and
fragmented nuclei whereas viable cells excluded the dye and did
not stain. The percentage of apoptotic nuclei was determined by
counting 600 cells from randomly selected ﬁelds and 3 replicate
dishes were examined for each experimental group. The percentage
of apoptotic cells was calculated as the number of cells that stained
blue/total cells counted×100.
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RNA was extracted from three different primary cultures trans-
fected with the complete HPV-16 genome using Trizol (Invitrogen).
Cellular DNA was digested with Turbo DNA-Free (Ambion, Inc) and
RNA was reverse transcribed using Superscript First Strand kit (Invi-
trogen). No RT controls were included to conﬁrm absence of cell
DNA. Real-Time PCR was performed using an iCycler IQ (Bio-Rad)
using triplicate reactions (50 μl) containing 25 μl of 2× SYBR-Green
Supermix, 0.4 μM of each forward and reverse primer, and 1 μl
cDNA. HPV-16 E6 primers were: forward GACCCAGAAAGTTACCACAG
and reverse GCAACAAGACATACATCGAC. HPV-16 E7 primers were:
forward ATGACAGCTCAGAGGAG and reverse TCATAGTGTGCCCAT
TAACAG. Beta-actin primers were: forward GGACTTCGAGCAAGAGA
TGG and reverse AGCACTGTGTTGGCGTACAG. Reactions were per-
formed for 40 cycles and melting temperature analysis was con-
ducted on each sample to check speciﬁcity of product. Relative
expression was calculated using the ΔΔCt method. Three housekeep-
ing genes (β-actin, GAPDH and keratin 14) were examined for nor-
malization and β-actin was chosen because erlotinib did not alter
expression. Potential effects or erlotinib on splicing of E6/E7 RNA
were measured PCR using primers for E6/E6* ACTGCAATGTTTCAG
GACCCA and TCAGGACACAGTGGCTTTT (Rosenberger et al., 2010)
and the cDNA samples used for RT-PCR.
Dual luciferase reporter gene assay
Cells were grown in 12 well plates and cotransfected with lipofec-
tamine (Invitrogen) for 3 hours using 0.5 μg of the NF-κB responsive
ﬁreﬂy luciferase reporter gene (Clontech), and 0.25 μg of a renilla lu-
ciferase reporter gene (Clontech). The latter promoter has weak ac-
tivity and served as an internal control for transfection efﬁciency.
Transfected cultures were maintained in KSFM for 24 hours prior to
measuring NF-κB activity using a dual luciferase assay (Promega).
Each transfection was performed in triplicate, and transfection exper-
iments were repeated 3 times using cells from different donors. Pos-
itive and negative controls for NF-κB activation included
cotransfection with a p65 expression vector or a vector containing
the IKBα dominant negative mutant, respectively.
Senescence assay
Cervical cells were infected with HPV-16 E6/E7 retroviruses and
plated for clonal growth assays as described. Cultures were treated
with a 1 μM erlotinib for various times ranging from 0 to 14 days.
Six cultures were removed every 2 days and returned to normal
KSFM without drug for an additional 10 days to examine whether
growth inhibition was reversible. Growth was assessed by measuring
colony forming ability in 3 dishes and senescence was determined in
the 3 remaining dishes using a β-galactosidase assay kit (Cell Signal-
ing Technology).
Statistical analysis
One way analysis of variance (ANOVA) was used to compare the
means of multiple experimental groups when data was distributed
normally, and the Kruskal–Wallis test was used for comparisons
when the distribution was not normal. Tukey's multiple comparison
test was used to compare differences between each pair of means. Re-
gression analysis was used to predict ID50 values from the results of
clonal growth and apoptosis experiments.
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